Response by Fox to Letter Regarding Article, "The COMPASS Trial: Net Clinical Benefit of Low-Dose Rivaroxaban Plus Aspirin as Compared With Aspirin in Patients With Chronic Vascular Disease".
作者信息
Fox Keith A A
机构信息
Centre for Cardiovascular Science, University of Edinburgh, United Kingdom(K.A.A.F.).
出版信息
Circulation. 2021 Jan 5;143(1):e3. doi: 10.1161/CIRCULATIONAHA.120.051368. Epub 2020 Dec 30.
Abstract
摘要
Zotero 插件